Literature DB >> 34558232

A 3D-Bioprinted Multiple Myeloma Model.

Di Wu1, Zongyi Wang1, Jun Li1, Yan Song2, Manuel Everardo Mondragon Perez1, Zixuan Wang1, Xia Cao1, Changliang Cao1, Sushila Maharjan1, Kenneth C Anderson2, Dharminder Chauhan2, Yu Shrike Zhang1.   

Abstract

Multiple myeloma (MM) is a malignancy of plasma cells accounting for ≈12% of hematological malignancies. In this study, the fabrication of a high-content in vitro MM model using a coaxial extrusion bioprinting method is reported, allowing formation of a human bone marrow-like microenvironment featuring an outer mineral-containing sheath and the inner soft hydrogel-based core. MM cells are mono-cultured or co-cultured with HS5 stromal cells that can release interleukin-6 (IL-6), where the cells show superior behaviors and responses to bortezomib in 3D models than in the planar cultures. Tocilizumab, a recombinant humanized anti-IL-6 receptor (IL-6R), is investigated for its efficacy to enhance the chemosensitivity of bortezomib on MM cells cultured in the 3D model by inhibiting IL-6R. More excitingly, in a proof-of-concept demonstration, it is revealed that patient-derived MM cells can be maintained in 3D-bioprinted microenvironment with decent viability for up to 7 days evaluated, whereas they completely die off in planar culture as soon as 5 days. In conclusion, a 3D-bioprinted MM model is fabricated to emulate some characteristics of the human bone marrow to promote growth and proliferation of the encapsulated MM cells, providing new insights for MM modeling, drug development, and personalized therapy in the future.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  bioprinting; bortezomib; coaxial extrusion; multiple myeloma; tocilizumab

Mesh:

Substances:

Year:  2021        PMID: 34558232      PMCID: PMC8940744          DOI: 10.1002/adhm.202100884

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   11.092


  69 in total

1.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Authors:  Yu-Tzu Tai; Patrick A Mayes; Chirag Acharya; Mike Y Zhong; Michele Cea; Antonia Cagnetta; Jenny Craigen; John Yates; Louise Gliddon; William Fieles; Bao Hoang; James Tunstead; Amanda L Christie; Andrew L Kung; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2014-02-25       Impact factor: 22.113

2.  NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Authors:  Kenneth C Anderson; Melissa Alsina; Djordje Atanackovic; J Sybil Biermann; Jason C Chandler; Caitlin Costello; Benjamin Djulbegovic; Henry C Fung; Cristina Gasparetto; Kelly Godby; Craig Hofmeister; Leona Holmberg; Sarah Holstein; Carol Ann Huff; Adetola Kassim; Amrita Y Krishnan; Shaji K Kumar; Michaela Liedtke; Matthew Lunning; Noopur Raje; Frederic J Reu; Seema Singhal; George Somlo; Keith Stockerl-Goldstein; Steven P Treon; Donna Weber; Joachim Yahalom; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2016-04       Impact factor: 11.908

Review 3.  Multiple myeloma.

Authors:  Shaji K Kumar; Vincent Rajkumar; Robert A Kyle; Mark van Duin; Pieter Sonneveld; María-Victoria Mateos; Francesca Gay; Kenneth C Anderson
Journal:  Nat Rev Dis Primers       Date:  2017-07-20       Impact factor: 52.329

Review 4.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

5.  Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.

Authors:  Yi Zhou; Xiaoting Liu; Junxin Xue; Lulu Liu; Tao Liang; Wen Li; Xinying Yang; Xuben Hou; Hao Fang
Journal:  J Med Chem       Date:  2020-04-23       Impact factor: 7.446

6.  A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.

Authors:  Julia Kirshner; Kyle J Thulien; Lorri D Martin; Carina Debes Marun; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

7.  Combination of nano-hydroxyapatite and curcumin in a biopolymer blend matrix: Characteristics and drug release performance of fibrous composite material systems.

Authors:  Ş Melda Eskitoros-Togay; Y Emre Bulbul; Nursel Dilsiz
Journal:  Int J Pharm       Date:  2020-10-02       Impact factor: 5.875

8.  Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.

Authors:  Maaike Vj Braham; Anil K Deshantri; Monique C Minnema; F Cumhur Öner; Raymond M Schiffelers; Marcel Ham Fens; Jacqueline Alblas
Journal:  Int J Nanomedicine       Date:  2018-11-29

Review 9.  3D Bioprinting Strategies for the Regeneration of Functional Tubular Tissues and Organs.

Authors:  Hun-Jin Jeong; Hyoryung Nam; Jinah Jang; Seung-Jae Lee
Journal:  Bioengineering (Basel)       Date:  2020-03-31

10.  ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Prosurvival Autophagy.

Authors:  Huimin Zhang; Yuhui Pang; Chuanbao Ma; Jianying Li; Huaquan Wang; Zonghong Shao
Journal:  Oncol Res       Date:  2017-09-11       Impact factor: 5.574

View more
  2 in total

Review 1.  Perspectives for 3D-Bioprinting in Modeling of Tumor Immune Evasion.

Authors:  Rafał Staros; Agata Michalak; Kinga Rusinek; Krzysztof Mucha; Zygmunt Pojda; Radosław Zagożdżon
Journal:  Cancers (Basel)       Date:  2022-06-26       Impact factor: 6.575

Review 2.  Patient-derived cancer models: Valuable platforms for anticancer drug testing.

Authors:  Sofia Genta; Bryan Coburn; David W Cescon; Anna Spreafico
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.